Delayed or upfront brain radiotherapy in treatment-naïve lung cancer patients with asymptomatic or minimally symptomatic brain metastases and ALK rearrangements (DURABLE). 1 BRAF V600-mutated tumors ...
ORLANDO, Fla. — A second phase 2 trial with the tyrosine kinase 2 (TYK2) inhibitor deucravacitinib has met the primary efficacy endpoints for the treatment of the skin manifestations of cutaneous ...
The novel serotonin norepinephrine reuptake inhibitor (SNRI) ammoxetine may effectively treat major depressive disorder (MDD) while avoiding some side effects common to other antidepressants, new ...
Demonstrated a favorable safety and tolerability profile for VG-3927 across all cohorts, including elderly participants, with no serious adverse events reported. Achieved robust and dose-dependent ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback